Jane Knöchel

发表

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

K. Psachoulia, G. Law, H. Heerspink, 2021, Kidney international reports.

An oral antisense oligonucleotide for PCSK9 inhibition

P. Gennemark, B. Monia, M. Hölttä, 2021, Science Translational Medicine.

Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans

J. Schumi, A. Andréasson, M. Ekstedt, 2022, Hepatology communications.

Understanding and reducing complex systems pharmacology models based on a novel input–response index

W. Huisinga, C. Kloft, Jane Knöchel, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

C. Nilsson, I. Azarov, C. Dota, 2022, British journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects

K. Nelander, E. Lindstedt, H. Ericsson, 2021, Clinical Drug Investigation.

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.

A. Gabrielsen, E. Grove, E. Prescott, 2022, International journal of cardiology.

Deriving mechanism‐based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin

W. Huisinga, C. Kloft, Jane Knöchel, 2023, CPT: pharmacometrics & systems pharmacology.

A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

P. Gennemark, B. Hamrén, C. Nilsson, 2022, CPT: pharmacometrics & systems pharmacology.